Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
Tumor Organoid Tech Advances Toward a Sci-Fi Future
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.
Cancer evolution study reveals biology of glioma progression
July 14, 2026
A type of brain cancer, called glioma, tends to progress toward greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
The findings showcase the power of modern laboratory technology for illuminating cancer development, and could inform future treatments and prognostic measures for gliomas.
Discovery Could Lead to Drug Therapy for Hypopigmentation Conditions
July 14, 2026
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders.
Cancer Evolution Study by EIPM Researcher Reveals Biology of Glioma Progression
July 10, 2026
A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
2026 Second Quarter EIPM Director's Memo
July 7, 2026
Dear Friends & Members of the Englander Institute,
Welcome to the second quarterly external newsletter of 2026!
July 2026 EIPM Director's Memo
July 2, 2026
Dear Friends & Members of the Englander Institute,
I hope you enjoy this abbreviated edition of the EIPM Director's Memo. There was a lot of content in the previous edition that covered May and the first two weeks of June, but there is still plenty to read and enjoy here.
Thank you again for your continued hard work and dedication to our mission, and best wishes for a fun & relaxing holiday weekend!
Sincerely,
Olivier Elemento, Ph.D.
Rare Stem T Cells May Hold the Key to Fighting Chronic Diseases
July 2, 2026
T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged campaign against a chronic condition — like a viral infection, or cancer — the body needs a steady supply of these killer troops. Where and how these killer troops are generated has been a mystery.
PSA Levels Alone May Not Reflect Prostate Cancer Growth
July 1, 2026
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University. In some cases, cancer progression was detected on scans even when PSA levels were undetectable.
Dr. Eleni Andreopoulou earns an Honorary Professorship from the University of Ioannina Medical School in Greece
June 26, 2026
Congratulations to Cancer Therapeutics program and EIPM member Dr. Eleni Andreopoulou on earning an Honorary Professor of Medicine from her alma mater at the University of Ioannina (UoL) Medical School in Greece in recognition of her contributions to teaching and mentorship.
Dr. Andreopoulou is the first woman to receive this designation, which honors distinguished, multifaceted, and longstanding contributions to education, research, and the advancement of healthcare in the service of human wellbeing.